Yttrium-90 radioembolization for colorectal cancer liver metastases: a prospective cohort study on circulating angiogenic factors and treatment response

EJNMMI Research

Table 1 Baseline characteristics

Characteristic (total number of patients n = 42)
Gender (number of patients)
Female	13
Male	29
Age (years)
Mean (range)	62 (34–83)
ECOG performance status (number of patients)
0	23
1	17
2	2
Extrahepatic disease (number of patients)^a
None	30
Lymph node	7
Lung	3
Bone	3
Local recurrence	3
Other^c	4
Baseline level (number of patients)
Alkaline phosphatase
Elevated	34
Normal	8
Leucocytes
Elevated	0
Normal	42
Primary tumour surgically resected (number of patients)
Yes	39
No	3
Previous liver-directed treatment (number of patients)
Segmentectomy	5
Radiofrequency/microwave ablation	4
Hemihepatectomy	3
Other^b	3
Liver metastases (number of patients)
Synchronous	32
Metachronous	10
kRAS status (number of patients)
Wild type	17
Mutation	9
Unknown	16
Previous systemic therapy lines (number of patients)
0	0
1	15
2	16
>2	11
Received bevacizumab (number of patients)
Yes	25
No	17
Tumour load as percentage of liver volume (number of patients)
<25%	36
26–50%	6
>50%	0
Mean % (range)	15 (1–50)
Injected activity (MBq)	1508 (670–3675)
Liver dose (Gy)^d	44.3 (24.1–87.5)

Baseline characteristic of 42 patients
^aNumbers add to more than 42 because some patients had extrahepatic disease at more than one site
^bTransarterial chemoembolization n = 1, radiotherapy n = 1, open/close procedure for intended RFA n = 1
^cBrain n = 1, adrenal gland n = 2, peritoneal lesion n = 1
^dAssuming homogeneous distribution of administered activity
MBq megabecquerel, Gy gray